



Robert W. Jones
Senior Vice President
U.S. Government Relations

Pfizer Inc
1275 Pennsylvania Ave, NW, Suite 600
Washington, DC 20004
Tel 202 624-7518 Robert.Jones@pfizer.com

May 12, 2020

Mr. Peter Maybarduk
Access to Medicines Director
Public Citizen
1600 20th ST, NW
Washington, DC 20009

Dear Mr. Maybarduk,

We received your letter, dated April 27, 2020, addressed to our CEO Albert Bourla. Thank you for reaching out during this unprecedented time. Pfizer recognizes the public concern regarding the current situation, especially as it relates to patient access and affordability. We are actively monitoring the situation across the globe, assessing the implications to our patients, colleagues and company, and taking actions to support continued health and safety. This involves protective measures for our colleagues, in-kind and monetary donations to impacted areas, diligent monitoring of our global supply network and deploying resources – both people and financial – in the race to develop antiviral therapies and coronavirus vaccines.

We believe it is our responsibility to help protect the most vulnerable from this disease and are putting the full weight of our resources behind our comprehensive COVID-19 response, which includes expanding our patient assistance programs. We are evolving our U.S. Patient Assistance Program, Pfizer RxPathways, and donating additional critical medicines and vaccines in the U.S. We have launched a public service announcement that raises awareness of Pfizer RxPathways to connect with patients, and a new online application, enrollment & reorder option for the Patient Assistance Program, called Pfizer PAP Connect. Pfizer PAP Connect enables eligible new and re-enrolling patients and their healthcare providers to begin and complete the application process and manage their enrollment, including refills, completely online for some medicines. We are also reaching out to existing program utilizers to inform them of this new option and pursuing broader communications to help raise awareness of the platform.

Pfizer is committed to pricing our medicines in a way that reflects the benefit they bring to patients and society while enabling us to continue to invest in new medicines. In setting the prices of our medicines, we may consult with many stakeholders, including advocacy groups such as yours, as well as healthcare professionals, patients and payers to understand the medicine's clinical, economic and humanistic benefits and develop an evidence-based approach to its value. After a medicine is approved for use by patients, our work doesn't end. We continue to invest in a medicine through its entire lifecycle – monitoring for safety, analyzing real-world data, and often undertaking additional research and development. We may adjust the prices of our medicines and vaccines based on ongoing investments, new uses and on-going studies, amongst other factors. Lastly, we have a long history of and continue to work in partnership with governments and others in the healthcare sector to identify and implement solutions that relieve patient affordability burdens.

Again, thank you for reaching out; we welcome the opportunity to continue to have an open dialogue about how best to address patient access and affordability.

Sincerely,